News
Menopause at work: Women face challenges but receive minimal support, study reveals
Women cited working during menopause to be challenging reporting both physical and emotional symptoms
Women in the workforce face ‘significant’ challenges due to menopause, but receive minimal support from employers, according to a new survey from Carrot Fertility.
Carrot, a US fertility healthcare and family-forming benefits provider, commissioned the survey ahead of Menopause Awareness Month to understand the effects of menopause on careers, identify the support available and bring more awareness to menopause.
An estimated one billion women worldwide will have experienced menopause by 2025, with millions more going through perimenopause.
Of the 1,000 people experiencing perimenopause or menopause across the US who were surveyed, the vast majority of respondents (79 per cent) describe working during menopause as challenging, more than other common life stages, including starting a new job (75 per cent describe as challenging), starting a family (70 per cent), or getting a promotion (62 per cent).
When asked what age decade is the most challenging for being in the workplace, respondents ranked their 50s as number one, well ahead of second-ranked 20s, according to the study.
Most women reported the need to take time off or faced other serious challenges in the workplace during menopause and perimenopause.
More than half of women (54 per cent) have encountered at least one menopause-driven work challenge, including loss of work time and job security concerns.
Among the nearly 40 per cent of respondents who took time off due to perimenopause or menopause symptoms, 71 per cent lost more than 40 hours of work time, and 30 per cent reported losing more than a month of work time altogether.
Of those who took time off, 59 per cent felt they needed to conceal the reason for the time away.
Other workplace challenges tied to menopause reported by respondents include perceived losses to credibility in the workplace, worries over job loss due to menopause stigma, and lost work friendships.
“We’ve made tremendous progress around the ability to understand and address the fertility challenges impacting younger individuals in their work life, but we are woefully behind when it comes to supporting employees with their fertility healthcare needs as they age,” said Tammy Sun, founder and CEO, Carrot Fertility.
“The findings of this report spotlight the real challenges menopausal women in the workplace struggle with, including lost productivity and concerns over job security. The survey also validates the need for employers and business leaders to provide age-inclusive fertility benefits for employees.”
Most women surveyed were unfamiliar with workplace menopause benefits but highly supportive of the concept, with 82 per cent of respondents see such benefits as valuable.
When asked what type of menopause benefits they deem valuable, a large majority of respondents cited fundamental benefits, such as medical care and support, counselling and therapy, and support groups, as well as other offerings like menopause mentoring and office menopause rooms to manage their symptoms.
While there is high support for employer-provided menopause benefits from people experiencing menopause and perimenopause, such offerings are rare and typically limited to flexible scheduling.
Only eight per cent say their employer has offered significant support for menopause, compared to 59 per cent who report no support at all. Among the 21 per cent whose employers have offered significant or minor support, flexible scheduling is the most common.
The survey showed if employers opted to offer menopause benefits, they would gain significant advantages, including employee retention.
Other advantages for employers who offer benefits are increased job satisfaction and productivity. Among the respondents, 92 per cent have at least one reason for believing menopause benefits should be provided by employers, such as employee retention and workplace fairness.
Few respondents feel prepared for menopause, with 65 per cent describe their experience as difficult and only eight per cent report feeling very prepared and informed for the overall experience of menopause.
Despite the lack of preparedness, women shared that they’ve experienced both physical and emotional symptoms during menopause, including hot flashes, fatigue, night sweats and weight gain.
Mood changes and anxiety were the most commonly reported emotional and mental health symptoms.
The findings of Carrot’s survey highlight the perception that discussing menopause at work is taboo, and the significant impact menopause has on respondents’ personal and professional relationships.
The majority of people surveyed shared that they feel uncomfortable discussing menopause at work, having to seek support from other sources instead.
“The dramatic hormonal changes stemming from menopause can result in symptoms that negatively impact people physically, mentally, and emotionally, in both their personal and professional lives, as confirmed by this survey,” said Dr Asima Ahmad, MD, MPH, co-founder and chief medical officer at Carrot Fertility.
“What’s also crystal clear from this survey is the diversity of support and benefits women in the workplace deem critical to their productivity, ranging from medical care to counselling and emotional support groups. We hope employers are taking note.”
Carrot aims to help employers and health plans provide equal access to fertility care regardless of age, race, income, sex, sexual orientation, gender identity, marital status or location.
Earlier this year, the company developed a new line of clinically-validated, age-inclusive fertility benefits for employees going through every stage of menopause and low testosterone.
Customers have now the option to add support for menopause and low testosterone as part of their fertility benefits package, having access to providers through a specialised network, clinically supervised education and intimate group support.
Diagnosis
Lung cancer drug shows breast cancer potential
Ovarian cancer cells quickly activate survival responses after PARP inhibitor treatment, and a lung cancer drug could help block this, research suggests.
PARP inhibitors are a common treatment for ovarian cancer, particularly in tumours with faulty DNA repair. They stop cancer cells fixing DNA damage, which leads to cell death, but many tumours later stop responding.
Researchers identified a way cancer cells may survive PARP inhibitor treatment from the outset, pointing to a potential way to block that response. A Mayo Clinic team found ovarian cancer cells rapidly switch on a pro-survival programme after exposure to PARP inhibitors. A key driver is FRA1, a transcription factor (a protein that turns genes on and off) that helps cancer cells adapt and avoid death.
The team then tested whether brigatinib, a drug approved for certain lung cancers, could block this response and boost the effect of PARP inhibitors. Brigatinib was chosen because it inhibits multiple signalling pathways involved in cancer cell survival.
In laboratory studies, combining brigatinib with a PARP inhibitor was more effective than either treatment alone. Notably, the effect was seen in cancer cells but not normal cells, suggesting a more targeted approach.
Brigatinib also appeared to act in an unexpected way. Rather than working through the usual DNA repair routes, it shut down two signalling molecules, FAK and EPHA2, that aggressive ovarian cancer cells rely on. FAK and EPHA2 are proteins that relay survival signals inside cells. Blocking both at once weakened the cells’ ability to adapt and resist treatment, making them more vulnerable to PARP inhibitors.
Tumours with higher levels of FAK and EPHA2 responded better to the drug combination. Other data link high levels of these molecules to more aggressive disease, pointing to potential benefit in harder-to-treat cases.
Arun Kanakkanthara, an oncology investigator at Mayo Clinic and a senior author of the study, said: “This work shows that drug resistance does not always emerge slowly over time; cancer cells can activate survival programmes very early after treatment begins.”
John Weroha, a medical oncologist at Mayo Clinic and a senior author of the study, said: “From a clinical perspective, resistance remains one of the biggest challenges in treating ovarian cancer. By combining mechanistic insights from Dr Kanakkanthara’s laboratory with my clinical experience, this preclinical work supports the strategy of targeting resistance early, before it has a chance to take hold. This strategy could improve patient outcomes.”
Insight
Higher nighttime temps linked to increased risk of autism diagnosis in children – study
Entrepreneur
Kindbody unveils next-gen fertility platform
-
Insight4 weeks agoDesigner perfumes recalled over banned chemical posing fertility risk
-
Insight2 weeks agoParents sue IVF clinic after delivering someone else’s baby
-
Insight3 weeks agoWomen’s health could unlock US$100bn by 2030
-
Fertility4 weeks agoChina’s birth rate hits record low despite government fertility efforts
-
Menopause3 weeks agoHRT linked to greater weight loss on tirzepatide
-
Entrepreneur6 days agoUS startup builds wearable hormone tracker
-
Menopause2 weeks agoFlo Health and Mayo Clinic publish global perimenopause awareness study
-
News4 weeks agoVerdane invest in Clue to accelerate the future of women’s health







2 Comments